Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6577653 | 0.93 | THRB (0.35) | ALDH1A1LMNATSHRSMN1; SMN2THRB | |
| SCHEMBL9702342 | 0.85 | LMNA (0.46) | ALDH1A1LMNATSHRSMN1; SMN2HSD17B10 | |
| SCHEMBL4882493 | 0.85 | LMNA (0.52) | ALDH1A1LMNATSHRSMN1; SMN2THRB | |
| SCHEMBL6925076 | 0.85 | LMNA (0.46) | ALDH1A1LMNATSHRSMN1; SMN2HSD17B10 | |
| SCHEMBL15027 | 0.85 | — | — | |
| SCHEMBL236338 | 0.84 | ALDH1A1 (0.47) | ALDH1A1LMNATSHRSMN1; SMN2HSD17B10 | |
| SCHEMBL7288108 | 0.84 | ALDH1A1 (0.59) | ALDH1A1LMNATSHRSMN1; SMN2HSD17B10 | |
| SCHEMBL8996397 | 0.84 | ALDH1A1 (0.47) | ALDH1A1LMNATSHRSMN1; SMN2HSD17B10 | |
| SCHEMBL6441220 | 0.84 | ALDH1A1 (0.59) | ALDH1A1LMNATSHRSMN1; SMN2HSD17B10 | |
| SCHEMBL21067647 | 0.82 | LMNA (0.38) | ALDH1A1LMNATSHRSMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117844431-A | Thermoplastic polyurethane adhesive, preparation method and application thereof | 万华化学集团股份有限公司 | 2024-04-09 | — | — | CN | claimed |
| CN-114316197-B | Thermoplastic polyurethane adhesive with low polarity and high heat resistance and application thereof | 万华化学集团股份有限公司 | 2023-07-14 | — | — | CN | claimed |
| CN-114316197-A | Low-polarity high-heat-resistance thermoplastic polyurethane adhesive and application thereof | 万华化学集团股份有限公司 | 2022-04-12 | — | — | CN | claimed |
| US-8278451-B2 | Pseudoazulenyl nitrones | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2012-10-02 | — | — | US | claimed |
| US-8173630-B2 | Multipodal tethers for high-density attachment of redox-active moieties to substrates | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-08 | — | — | US | claimed |
| US-20100016349-A1 | PSEUDOAZULENYL NITRONES | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2010-01-21 | — | — | US | claimed |
| WO-2008002614-A2 | PSEUDOAZULENYL NITRONES | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2008-01-03 | — | — | WO | claimed |
| EP-0779888-B1 | PYRIMIDO [5,4-D]PYRIMIDINES, DRUGS CONTAINING THESE COMPOUNDS, THEIR USE, AND PROCESS FOR PREPARING THEM | BOEHRINGER INGELHEIM PHARMA (DE) | 1999-04-28 | — | — | EP | claimed |
| US-5707989-A | ANTITUMOR AGENTS, INHIBITING SIGNAL TRANSDUCTION MEDIATED BY TYROSINE KINASES | DR. KARL THOMAE GMBH (DE) | 1998-01-13 | — | — | US | claimed |
| CN-117881432-A | Porphyrin-hydrogen porphyrin compounds, compositions comprising the same, and methods of use thereof | 北卡罗莱纳州立大学 | 2024-04-12 | — | — | CN | disclosed |
| CN-117844431-A | Thermoplastic polyurethane adhesive, preparation method and application thereof | 万华化学集团股份有限公司 | 2024-04-09 | — | — | CN | disclosed |
| EP-4319823-A1 | PORPHYRIN-HYDROPORPHYRIN COMPOUNDS, COMPOSITIONS COMPRISING THE SAME AND METHODS OF USE THEREOF | North Carolina State University (US) | 2024-02-14 | — | — | EP | disclosed |
| WO-2022216927-A9 | PORPHYRIN-HYDROPORPHYRIN COMPOUNDS, COMPOSITIONS COMPRISING THE SAME AND METHODS OF USE THEREOF | NORTH CAROLINA STATE UNIVERSITY (US) | 2023-09-14 | — | — | WO | disclosed |
| CN-114316197-B | Thermoplastic polyurethane adhesive with low polarity and high heat resistance and application thereof | 万华化学集团股份有限公司 | 2023-07-14 | — | — | CN | disclosed |
| US-20070027311-A1 | Methods and intermediates for the synthesis of porphyrins | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-02-01 | — | — | US | disclosed |
| US-20070027312-A1 | Methods and intermediates for the synthesis of porphyrins | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-02-01 | — | — | US | disclosed |
| US-20060194960-A1 | infections, burns, sepsis, ulcers, periodontal disease, atherosclerosis, cosmetic and dermatologic conditions, acne, tissue sealing, neoplastic disease or cancer; active agents in photodynamic therapy, luminescent compounds in flow cytometry, solar cells, light harvesting arrays, molecular memory devices | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-08-31 | — | — | US | disclosed |
| US-5885968-A | FOR HYPOLIPIDEMIC MEDICINES | RIJKSUNIVERSITEIT TE LEIDEN (NL) | 1999-03-23 | — | — | US | disclosed |
| EP-0655070-B1 | TRIANTENNARY CLUSTER GLYCOSIDES, THEIR PREPARATION AND USE | UNIV LEIDEN (NL) | 1998-07-22 | — | — | EP | disclosed |
| US-5707989-A | ANTITUMOR AGENTS, INHIBITING SIGNAL TRANSDUCTION MEDIATED BY TYROSINE KINASES | DR. KARL THOMAE GMBH (DE) | 1998-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194960-A1 | infections, burns, sepsis, ulcers, periodontal disease, atherosclerosis, cosmetic and dermatologic conditions, acne, tissue sealing, neoplastic disease or cancer; active agents in photodynamic therapy, luminescent compounds in flow cytometry, solar cells, light harvesting arrays, molecular memory devices | PCNA, SCD, BCL6 | ALDH1A1 205/4885LMNA 2225/4885TSHR 4693/4885 |
| US-20070027312-A1 | Methods and intermediates for the synthesis of porphyrins | PPOX, DHPS, POR | ALDH1A1 567/4885LMNA 1601/4885TSHR 3840/4885 |
| US-20100016349-A1 | PSEUDOAZULENYL NITRONES | TXN2, NOX5, TXNRD2 | ALDH1A1 900/4885LMNA 652/4885TSHR 3186/4885 |
| US-20070027311-A1 | Methods and intermediates for the synthesis of porphyrins | PPOX, HMBS, CYC1 | ALDH1A1 917/4885LMNA 1169/4885TSHR 4480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.